New AI tool predicts brain tumour recurrence risk without costly genetic testing
New AI tool predicts brain tumour recurrence risk by analysing routine pathology slides, offering an alternative to costly genetic testing for many patients with meningiomas. Developed by researchers at Mayo Clinic and collaborators, the deep learning model was trained using pathology images, tissue samples and clinical data from 672 patients. The system extracts molecular and prognostic…
















